Get the Stockscreener App
5.87
0.86%
0.05
Pre-market:
5.95
0.08
+1.36%
Kalaris Therapeutics Inc stock is traded at $5.87, with a volume of 166.33K.
It is up +0.86% in the last 24 hours and down -32.30% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$5.82
Open:
$5.79
24h Volume:
166.33K
Relative Volume:
2.42
Market Cap:
$134.59M
Revenue:
-
Net Income/Loss:
$-43.44M
P/E Ratio:
-1.3993
EPS:
-4.1951
Net Cash Flow:
$-43.18M
1W Performance:
-7.41%
1M Performance:
-32.30%
6M Performance:
+19.07%
1Y Performance:
-9.13%
1-Day Range:
$5.42
$5.99
1-Week Range:
$5.42
$6.64
52-Week Range:
$2.14
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
5.87 | 133.44M | 0 | -43.44M | -43.18M | -4.1951 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[EFFECT] Kalaris Therapeutics, Inc. SEC Filing - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers $100M ATM program with TD Cowen - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers 5,000,000 shares for resale - Stock Titan
Death Cross: Will Kalaris Therapeutics Inc benefit from rate cuts2026 Macro Moves & Breakout Confirmation Alerts - baoquankhu1.vn
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift - TipRanks
Kalaris Therapeutics IncMatthew Gall Resigns As CFO Effective April 14, 2026SEC Filing - TradingView — Track All Markets
CFO exit at Kalaris Therapeutics (NASDAQ: KLRS) as Brett Hagen takes finance lead - Stock Titan
Volume Summary: Is Kalaris Therapeutics Inc attractive for institutional investors2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Kalaris Therapeutics (NASDAQ: KLRS) files $350M shelf, $100M ATM - Stock Titan
Kalaris Therapeutics (NASDAQ: KLRS) registers 5.0M shares resale prospectus - Stock Titan
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Growth Value: Should you avoid Kalaris Therapeutics Inc stock right nowQuarterly Performance Summary & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug PreEarnings: Can Kalaris Therapeutics Inc weather a recessionShare Buyback & Smart Swing Trading Alerts - baoquankhu1.vn
Bond Watch: Is Kalaris Therapeutics Inc attractive for institutional investors2026 Price Action Summary & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Ideas Watch: Is Kalaris Therapeutics Inc a good stock for dollar cost averagingTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Brett Hagen Sells 1,915 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock - MarketBeat
Kalaris Therapeutics (KLRS) CAO sells stock and gets large option grant - Stock Titan
Morgan Stanley lists KLRS restricted stock vesting parcels (KLRS) in Form 144 notice - Stock Titan
Kalaris Therapeutics (KLRS) awards 222,000 stock options to director Andrew Oxtoby - Stock Titan
Kalaris Therapeutics (KLRS) CFO receives grant of 95,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) grants CMO 135,000 stock options - Stock Titan
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates - VisionMonday.com
Analyst Upgrade: Should you avoid Faraday Future Intelligent Electric Inc stock right nowFed Meeting & Pattern Based Trade Signal System - baoquankhu1.vn
Kalaris Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $(43.4M) Net Loss - TradingView
Kalaris Therapeutics (NASDAQ: KLRS) builds TH103 pipeline in retinal disease - Stock Titan
Kalaris Therapeutics Reports 2025 Financial Results, Highlights Positive TH103 nAMD Phase 1a Data and Strong Cash Position - Minichart
Kalaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
KLRS: Strong clinical progress and $118M cash position support operations through 2027 - TradingView
Kalaris (Nasdaq: KLRS) trims 2025 loss as $118M cash funds TH103 trials - Stock Titan
Retinal drug developer Kalaris posts $43M loss, funded into late 2027 - Stock Titan
Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen - MarketBeat
Raymond James Maintains Strong Buy on KLRS Kalaris Therapeutics Inc Mar 2026 - Meyka
William Blair reiterates Kalaris stock rating on TH103 potential By Investing.com - Investing.com Canada
Kalaris Therapeutics TH103: Next-Generation Anti-VEGF for Retinal Diseases Shows Promising Phase 1a Results and Extended Durability 23578 - Minichart
Stock Market Recap: Can Kalaris Therapeutics Inc weather a recessionPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay - Investing.com UK
Kalaris Updates TH103 Strategy and Highlights Cash Runway - TipRanks
Kalaris updates TH103 timelines, previews Phase 1b/2 data and extends cash runway into Q4 2027 - TradingView
Aug Analyst Calls: Is Kalaris Therapeutics Inc stock a good pick for beginners2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Kalaris Therapeutics Inc. stock benefit from green energy trendsQuarterly Trade Report & Fast Exit and Entry Strategy Plans - Naître et grandir
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
US Market Wrap: Is Kalaris Therapeutics Inc vulnerable to short sellersJuly 2025 Fed Impact & Short-Term Trading Alerts - baoquankhu1.vn
Jeffrey Bornstein - ProPublica
KLRS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kalaris Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
KLRS Should I Buy - Intellectia AI
Published on: 2026-02-28 06:52:09 - baoquankhu1.vn
ETFs Investing in Kalaris Therapeutics, Inc. Stocks - TradingView
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):